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 ABSTRACT: A successful unified pharmacophore/receptor model which has guided the 
synthesis of subtype selective compounds is reviewed in the light of recent developments both 
in ligand synthesis and structural studies of the binding site itself. The evaluation of 
experimental data in combination with a comparative model of the α1β2γ2 GABAA receptor 
leads to an orientation of the pharmacophore model within the Bz BS.  Results not only are 
important for the rational design of selective ligands, but also for the identification and 
evaluation of possible roles which specific residues may have within the benzodiazepine 
binding pocket. 
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The GABAA receptor is the major inhibitory neurotransmitter receptor of the central nervous 
system (CNS) and the site of action of a variety of pharmacologically and clinically important 
drugs, such as benzodiazepines, barbiturates, neuroactive steroids, anesthetics and 
convulsants.(Sieghart, 1995) It is now clear that these receptors regulate the excitability of the 
brain, anxiety, muscle tone, circadian rhythms, sleep, vigilance, memory and 
learning.(Sieghart and Ernst, 2005)  There are several disease states associated with the 
improper functioning of this protein, including anxiety, epilepsy[1], insomnia[2],  depression 
and bipolar disorder,[3, 4] schizophrenia,[5] as well as mild cognitive impairment and 
Alzheimer's disease,[6].   A role of GABAA receptors in drug and alcohol abuse has also been 
reported.[7-9].  
 GABAA receptors are composed of 5 subunits that form a central chloride channel and 
can belong to different subunit classes. A total of 19 subunits (6α, 3β, 3γ, 1δ, 1ε, 1π, 1θ, 3ρ) of 
the GABAA receptor have been cloned and sequenced from the mammalian nervous 
system.[10](Simon, Wakimoto et al., 2004) All these polypeptides possess an approximate 
molecular mass of ~ 50 kD and are structurally related.  Each subunit consists of a large 
extracellular region, which contains several potential glycosylation sites and a characteristic 
“cys-loop” formed by a covalent bond between two conserved cysteines.  This extracellular 
region is also important in contributing to the agonist GABA and modulatory benzodiazepine 
binding sites. The protein then traverses the lipid bilayer four times and has a large 
intracellular loop located between transmembrane regions 3 and 4 (M3 and M4).  This 
intracellular region contains possible phosphorylation sites necessary for regulation of the 
receptor.  The homology within each subunit class is about 60 – 80 %, while the homology 
between subunit classes is about 30 – 40 %.  In Figure 1  the proposed topology of a single 
GABAA receptor subunit is shown.  The pentameric structure of a ligand-gated ion channel is 
shown in Figure 2.[11, 12] 
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Figure 1. Proposed topology of a GABAA receptor subunit.  The extracellular domain begins 
with the N-terminus and M1-M4 represent the four transmembrane domains.  Figure 
reprinted with permission.[11] 
 
 
Figure 2.  Longitudinal (A) and cross-sectional (B) schematic representations of a ligand-gated 
ion channel.  The numbers 1-4 refer to the M1-M4 segments.  The M2 segment contributes to 
the majority of the pore lining within the membrane lipid bilayer.  Figures reprinted with 
permission.[12] 
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The existence of multiple GABAA receptor subunits can give rise to a large number of 
different GABAA receptor subtypes (Sieghart and Sperk, 2002). The majority of GABAA 
receptors, however, is composed of 1γ and 2α and 2β subunits. The presence of a γ subunit 
within a GABAA receptor is necessary for the formation of a benzodiazepine binding site that 
is located at the interface of an α and a γ subunit. Whereas the classical benzodiazepines, such 
as diazepam or flunitrazepam, exhibit a high affinity for receptors composed of α1βγ2, α2βγ2, 
α3βγ2 or α5βγ2 subunits (diazepam sensitive (DS) receptors), as well as for their less 
intensively investigated analogues containing the γ3 subunit, other benzodiazepine binding 
site ligands are also able to interact with α4βγ2 or α6βγ2 receptors (diazepam insensitive (DI) 
receptors), or with receptors containing γ1 subunits. (Sieghart, 1995) Receptors containing γ1 or 
γ3 subunits exhibit a quite low abundance in the brain (Mossier et al., 1994; Tögel et al., 1994; 
Pirker et al., 2000) and their contribution to the “in vivo” effects of benzodiazepine binding site 
(BZ BS) ligands currently is unclear.  
The concept of receptor multiplicity has been extremely valuable, in that different 
receptor subtypes reside within anatomically distinct regions of the brain and are responsible 
for different physiological and pathological processes [13-15]. For example, the α1βγ2 receptor 
subtype has a prominent role in seizure susceptibility and sedation,[16-18] the α2βγ2 and 
possibly also the α3βγ2 subtypes are involved in anxiety, whereas the α5βγ2 subtype has a 
prominent role in memory and learning (Table 1) [14, 19-21]. These distinctions have thus 
become a motivation for the design of subtype selective ligands in order to elicit a single 
specific response [14, 22-29]. Differences observed in the action of such drugs may be due to 
subtype-selective affinity and absolute and/or relative subtype-selective efficacy.[30] 
Table 1.  Action of benzodiazepines at GABAA α1−6 β3γ2 receptor subtypes.[31] 
Subtype Associated Effect 
α1 Sedation, anterograde amnesia,  
Some anticonvulsant action, ataxia  
α2 Anxiolytic, hypnotic (EEG), some muscle relaxation 
α3 Some anxiolytic action, some anticonvulsant action,  
Maybe some muscle relaxation 
α4 Diazepam-insensitive site 
α5 Cognition, temporal and spatial memory  
(Maybe memory component of anxiety) 
α6 Diazepam-insensitive site 
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Agonist binding to the receptor opens an intrinsic chloride ion channel, typically 
hyperpolarizing the cell membrane or at least opposing depolarization, thereby inhibiting 
neuronal transmission.  Bz BS ligands are allosteric modulators, unable to induce channel 
openings themselves, but function to vary the frequency and not the channel opening times. 
(Study and Barker, 1981)[32] Positive allosteric modulators at the benzodiazepine binding site 
(agonists) increase this frequency, while negative allosteric modulators (inverse agonists) 
decrease the frequency.  Currently it is not clear whether Bz BS ligands allosterically  modulate 
GABA affinity or channel gating.  Recent studies [33] (Ernst et al., 2005, Mol. Pharmacol. 68, 
1291) support the view that high-affinity classical benzodiazepines modulate α1β2γ2 GABAA 
receptors via allosteric coupling to channel gating.[34, 35]  Further studies are needed to 
determine whether the mechanism of modulation varies in different receptor subtypes.  
In recent years a unified pharmacophore/receptor model for agonists, antagonists and 
inverse agonists at the Bz BS was developed, using the techniques of chemical synthesis, 
radioligand binding and receptor mapping [36, 37]. The overlap of these different modulators 
within the Bz BS has been supported by experimental data.[38-40] Using this ligand-based 
pharmacophore/receptor model and our α1β2γ2 GABAA receptor models,[41] [42] the 
experimental data of recent and past years have been evaluated, and definite trends with 
regard to the orientation of the regions of the protein relative to the descriptors of the 
pharmacophore/receptor model have been identified and are presented in this work. The need 
to define such an orientation has been established,[43] since it permits  inspection of ligand 
docking studies and the identification of possible roles specific residues may have within the 
Bz BS. These roles may then be explored in future studies involving covalent labeling, site-
directed mutagenesis and structure-activity relationships, all of which contribute to the 
rational design of subtype-specific modulators of the Bz BS of GABAA receptors. 
 
The Unified Pharmacophore/Receptor Model 
    More than 150 agonists, antagonists and inverse agonists at the Bz BS [36, 37] which 
encompassed 15 structural families were used for generating the unified 
pharmacophore/receptor model. Although the relative affinities, efficacies and functional 
effects displayed by various ligands from the same structural class at the diazepam-sensitive 
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and diazepam-insensitive benzodiazepine binding sites were taken into account, the 
approximate locations of descriptors (hydrogen bond donor sites, hydrogen bond acceptor 
sites, lipophilic regions, and regions of steric repulsion) were based primarily on in vitro 
binding affinities. Ligands from different structural classes were then superposed on each 
other to satisfy the same descriptors, resulting in the unified pharmacophore model.  
 
 
Figure 3.  Relative locations of the descriptors and regions of the unified pharmacophore/ 
receptor model. The pyrazolo[3,4-c] quinolin-3-one CGS-9896 (dotted line), a diazadiindole 
(thin line), and diazepam (thick line) aligned within the unified pharmacophore/receptor 
model for the Bz BS.  H1 and H2 represent hydrogen bond donor sites within the Bz BS while 
A2 represents a hydrogen bond acceptor site necessary for potent inverse agonist activity in 
vivo.  L1, L2, L3 and LDi are four lipophilic regions and S1, S2, and S3 are regions of negative 
steric repulsion. LP = lone pair of electrons on the ligands. 
 
Briefly, the pharmacophore/receptor model consists of two hydrogen bond donating 
descriptors (H1 and H2), one hydrogen bond accepting descriptor (A2) and one lipophilic 
descriptor (L1). In addition to these descriptors, there are lipophilic regions of interaction (L2, 
L3 and LDi) as well as regions of negative steric repulsion (S1, S2 and S3).  While occupation of L2 
and/or L3 as well as interactions at H1, H2 and L1 are important for positive allosteric 
modulation, inverse agonists only require interactions with the H1, L1 and A2 descriptors of the 
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pharmacophore/receptor model for potent activity in vivo.[36, 44-47]  The LDi descriptor is a 
region of lipophilic interaction, for which the difference between the diazepam sensitive (DS) 
and the diazepam insensitive (DI) sub-pharmacophore models is most pronounced. Depicted 
in Figure 3 are the relative locations of the different descriptors and regions of the model.  
 
The structures of ligands frequently referred to in this paper are shown in Figure 4. 
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Figure 4.  Structures of ligands and their modulation at the α1 subtype. 
 
 
 The alignments of several Bz BS ligands within this model are shown in Figure 5.   
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Figure 5.  Alignments of several Bz BS ligands within the pharmacophore model.            
 
Included Volume Analysis of Ligands Binding to Receptors containing different Alpha 
Subunits 
The benzodiazepine binding site of αβγ2 GABAA receptors is strongly influenced by the type 
of α subunit present in these receptors as indicated by the existence of ligands exhibiting 
certain selectivity for receptors containing the respective α subunits. (Sieghart, 1995; Hevers 
and Lüddens, Sieghart and Ernst, 2005). If subtype selective ligands are then aligned within 
the pharmacophore model according to the resulting alignment rules,[48] their included 
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volumes can be constructed and used to compare the topologies of benzodiazepine binding 
pockets of different receptor subtypes. [48, 49]. Ligands employed in the included volume for 
each receptor subtype exhibited potent affinity (Ki ≤ 20 nM) at the respective receptor subtype. 
CL-218,872 5 (Ki = 57 nM at α1) and zolpidem 4 (Ki = 26.7 nM at α1) were added to the 
included volume of the α1β3γ2 subtype since they are both α1-subtype selective ligands. The 
major differences with regard to volume and affinity are shown below and are important for 
interpreting experimental data.  
 
 Figure 6: Overlap between pairs of included volumes derived from receptor subtype 
selective ligands: a) α1 and α2, b) α2 and α3, c) α4 and α6,   d) α1 and α6,  e) α1 and α5. Yellow 
color indicates overlapping regions and each grid measures 4 Å in width and height. In order 
to provide the connection between this figure and other figures, f) shows diazepam and the 
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descriptors of the unified pharmacophore model depicted in the included volume requirement 
of the  α1 subtype.  
The included volume requirements show some trends that are capable to explain 
subtype preferences of ligands and that have already guided substance development: 
1. The included volumes of the α1, α2, and α3 subtypes are similar both in size and topology.  This 
is consistent with the similar affinity profiles these subtypes displayed for classical 
benzodiazepine agonists, pyrazoloquinolinones and imidazobenzodiazepines (i-BZDs).[50-52]  
The included volume of the α1 subtype is slightly different from that of α2 and α3 subtype as 
indicated by the selective affinities of zolpidem, CL-218,872, 6-substituted β-carbolines (e.g. 6-
methylbenzyl amino betacarboline) and pyridodiindoles for this subtype and the space needed 
for accommodating these structures (Fig. 6a,b). [52]  Results from both the SAR studies and the 
included volume analysis imply that the α2 and α3 subtypes are very similar in shape, polarity 
and lipophilicity.  
2. The included volumes of the α1  and α4 or α6 subtypes are very different. Looking at Fig. 6d, it 
is evident that the included volume of the α6 subtype is significantly smaller than that of the 
α1 subtype. Especially the LDi region is much larger in α1 receptors. Contributions to the LDi 
region are derived in a large measure from 6-substituted β-carbolines and ring-A substituted 
pyrazoloquinolines, thus implying that occupation of the LDi region may be critical for ligand 
selectivity at the α1 subtype. This is supported by the finding that the LDi region was also 
larger for the α1β3γ2 subtype when compared with the α5β3γ2 subtype (Fig. 6e). 
3. L3 region is very small or non-existent for the α4  and α6 DI subtypes.  Based on the inability 
to bind 1,4-benzodiazepines, the lack of region L3 was believed to be responsible for the 
diazepam-insensitivity of these receptor subtypes (Fig. 6c, d).[36, 45]  With a few exceptions, β-
carbolines also do not bind to the α6β3γ2 receptor subtype, while i-BZDs and 
pyrazoloquinolinones (CGS series) represent the primary ligands that bind to this subtype.  
4. The L2 and LDi regions are slightly smaller for the α6 versus the α4 subtype.  The sequence of 
the α4 subunit is most homologous to the α6 subunit and it was determined that the 
pharmacological profiles of these DI sites toward classical benzodiazepines are very 
similar.[53]   Differences in the included volume of these DI sites are shown in Figure 6c.  
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5.  The L2 region contributes to α2 and α5 selectivity.  It has been observed that ligands with 
α2 and/or α5 selectivity are generally i-BZDs and have a lipophilic C(8)-substituent that 
occupies the L2 pocket. Based on ligands from various studies, examination of data in Figure 6  
illustrates that the L2 region is deeper and larger for the α2 and α5 subtypes, respectively, than 
for the corresponding α1 or α6 subtypes.[36, 37, 45, 54]  This L2 region seems to account for the 
selective affinity of ligands at the α5 subtype, as clearly illustrated in Figure 6e, whereas the 
same region may account for the selective efficacy observed at the α2 subtype. 
 
Recent Alignment of Non-Classical Bz BS Ligands support the Unified 
Pharmacophore/Receptor Model 
 Besides the major classes of Bz ligands used to define the model, several non-Bz ligands 
also fit within the pharmacophore/receptor model very well.  Examples include zopiclone (17) 
and its active enantiomer, the flavonoid 25 and the 8-chloropyrazolo[5,1-c][1,2,4]-benzotriazine 
5-oxide analog 38, as illustrated in Figs. 7 and 8, and Figs. 11 and 13. 
 
Zopiclone and its Active Enantiomer 
Since the sedative-hypnotic zopiclone 17 was first reviewed in Drugs in 1986,[55] a 
much larger body of clinical data has become available to permit a more detailed comparison 
of the non-benzodiazepine zopiclone with classical benzodiazepines. Results have shown that, 
regardless of the duration of action, zopiclone was generally at least as effective as 
benzodiazepines in the treatment of insomnia, although comparisons between zopiclone and 
flurazepam have produced inconsistent results. It was observed that zopiclone had a relatively 
low propensity to elicit residual clinical effects, such as difficulty in waking or reduced 
morning concentration. While tolerance to the effects of zopiclone was not noticed in short 
term clinical trials (≥ 4 weeks), the results from longer term studies were conflicting and, 
therefore, the potential for tolerance during long term administration of zopiclone was 
unclear. Rebound insomnia to a level above that at baseline can occur after withdrawal of 
zopiclone. However, on the basis of data from short term studies, this does not appear to be 
common. Evaluation of prescriptions filled has indicated that zopiclone does not have a high 
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dependence potential, at least in those who are not regular drug abusers/addicts. Zopiclone 
was well-tolerated in both the elderly and younger patients with insomnia. A bitter after-taste 
was usually the most common adverse event, but was relatively infrequent at 3.6 % in the 
largest available post-marketing study. Thus, zopiclone has now been firmly established as an 
effective and well-tolerated sleep agent.[56] 
The structure and alignment of zopiclone within the unified pharmacophore/receptor 
model is shown in Figure 7. The centroid of the pyridine moiety of zopiclone overlapped with 
region L1 of the receptor, while the lone pair of electrons of the carbonyl oxygen (O) atom 
interacted with H1 of the receptor to form a hydrogen bond between the ligand and the 
receptor.  A second hydrogen bond was formed between the amide carbonyl oxygen atom 
(LP) and H2 of the receptor protein (Figure 7). 
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Figure 7.  Structure of zopiclone 17, its alignment within the pharmacophore/receptor model 
and rotated 90 degrees.  
 
However, a recent study by Sepracor [57] indicated that one of the enantiomers of 
zopiclone was much more active than zopiclone itself.  This may be the result of receptor 
subtype-selective efficacy or simply a pharmacokinetic effect, but the 
pharmacophore/receptor model developed here revealed that the active enantiomer fits better 
into the included volume of the α1β3γ2 subtype than zopiclone 17 itself (Figure 8). This 
enantiomer has just been approved by the FDA for treatment of insomnia. 
.   
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Figure 8. Alignment of zopiclone 17 (left) and its active enantiomer (right) in the included 
volume of the pharmacophore/receptor model for the α1β3γ2 subtype.   
 
SH-053BZ Enantiomers 
 In pursuing this approach using BZ enantiomers, the behavioral activity of three newly-
synthesized compounds,[58] functionally selective for α2, α3 and α5-containing subtypes of 
GABAA receptors (SH-053-S-CH3 and SH-053-S-CH3-2’F), or essentially selective for α5 
subtypes (SH-053-R-CH3) were examined. Motor influence was tested in the elevated plus 
maze, spontaneous locomotor activity and rotarod test, which are considered primarily 
predictive of the anxiolytic, sedative and ataxic influence of BZs, respectively. There was 
substantially diminished ataxic potential of BZ site agonists devoid of α1 subunit-mediated 
effects, with preserved anti-anxiety effects at 30 mg/kg of SH-053-S-CH3 and SH-053-S-CH3-
2’F. However, all three ligands, dosed at 30 mg/kg, decreased spontaneous locomotor activity, 
suggesting that sedation may be partly dependent on activity mediated by α5-containing 
GABAA receptors. Such an effect could not have been observed previously, because to date, all 
apparently non-sedating BZ receptor ligands, which are devoid of activity at α1-containing 
GABAA receptors, engendered essentially antagonist[59] or only partial agonist efficacy at α5-
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containing GABAA receptors.[60] Therefore, it cannot be ruled out that substantial efficacy at 
α5-containing GABAA receptors may contribute to sedative effects besides the effects on 
learning and memory processes.[61, 62] This is supported by two sets of data which indicate 
the possibility of substantial motor influence via α5-GABAA receptor modulation: In the spinal 
cord, somatic and preganglionic motoneurons (lamina IX and lateral cell column) exhibited a 
moderate to strong staining for the α5 subunit, suggesting a possible influence of receptors 
containing these subunits in motor behavior.[63] In addition, the knock-in mice harboring the 
α5 subunit insensitive to diazepam are refractory to development of tolerance to the sedative 
effect of diazepam dosed subchronically. Such a tolerance development might have been 
caused by a downregulation of receptors containing α5 subunits in the appropriate brain 
regions of wild-type mice.[64] These two sets of evidence indicate that the motor influence of 
α5-GABAA receptor modulation is not necessarily an indirect consequence of the established 
effects on learning and memory processes.[61, 62] Hence, it has been hypothesized[58] that 
locomotor activity changes induced by ligands possessing a substantial α5-efficacy may be, at 
least partly, contributed by modulation at GABAA receptors containing the α5 subunit. It 
therefore could be of importance to avoid substantial agonist potentiation of α5-subunits by 
candidate anxioselective anxiolytics, if clinical sedation is to be avoided. Nevertheless, as a 
caveat to all studies examining sedation, it should be remembered that a decrease in 
automatically measured locomotor activity can be due to a variety of causes other than 
sedation, including the occurrence of stereotyped behavior, motor impairments or pain.[65] To 
dissect these overlaps in activity und uncertainties, much is expected from screening of even 
more selective BZ site ligands in the future. 
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Figure 9. Structures and conformations of SH-053-S-CH3 (A1-A3) and SH-053-R-CH3 (B1-B3). 
The molecular modeling was carried out as described in Zhang et al, 1995 and He et al, 2000. 
SH-053-S-CH3 fits to the pharmacophore within the included volume of the α2 subtype (A2); 
A3) is the same image rotated 90 degrees. It can be clearly seen that this conformer fits within 
the included volume. SH-053-R-CH3 fit to the pharmacophore in the included volume of the 
α2 subtype (B2); B3) is the same image rotated 90 degrees. The R-CH3 at the prochiral center 
C4 changes the conformation of the molecule causing the pendant 6-phenyl to stick outside the 
included volume, consequently this ligand is not efficacious at the α2 subtype. It simply does 
not interact strongly with α1, α2 or α3 subtypes. 
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Figure 10. Concentration-effect curves for SH-053-S-CH3 and SH-053-R-CH3 on α1β3γ2, α2β3γ2, 
α3β3γ2, and α5β3γ2 GABAA receptors. Data points represent means ± SEM from at least 4 
oocytes from ≥ 2 batches.  
 
Flavonoids  
 Flavonoids represent a class of non-Bz ligands that fit extremely well within the unified 
pharmacophore/receptor model. These compounds are a class of natural products isolated 
from a variety of herbal plants and employed as tranquilizers in folk medicine.  They exhibit a 
wide range of biological activity, such as antiviral, anti-inflammatory, antithrombotic, 
antioxidant and estrogenic effects.[66, 67]  Flavonoids also displayed potent anxiolytic effects 
and appeared devoid of myorelaxant, amnesic or sedative actions. Haberlein et al. has shown 
that the steric orientation of the substituents which lie coplanar to the aromatic ring was 
crucial for ligand affinity to the Bz BS.[68]  This was especially true for the C(5) and C(6) 
positions. Furthermore, the recent work of Huang et al. indicated that 6,3’-dinitroflavone 25 
exhibited a Ki value of 12 nM at the Bz BS (Table 2) and was an extremely potent anxiolytic 
devoid of muscle relaxant effects.  The 6-Br-3’-nitroflavone 26 also demonstrated increased 
binding affinity, however, the anxiolytic effect was lower than the dinitroanalog 25.[69] 
 
Table 2.  Affinities of a series of flavonoid ligands for benzodiazepine receptors.[69]                                      
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O
O
R3'
R6 5
7
8
3
2
1'
4'
5'
6'
2'
 
Compound R6 R3’ Ki (nM)
20 F NO2 182 
21 Cl NO2 8.0 
22 Br Cl 17.0 
23 Cl Br 23.0 
24 Br Br 19.1 
25 NO2 NO2 12.0 
26 Br NO2 1.0 
 
 The flavonoids 21, 25 and 26 fit very well within the unified pharmacophore/receptor 
model.  The alignment of 6,3’-dinitroflavone 25 within the α2β3γ2 subtype is shown in Figure 
11.  The centroid of the phenyl moiety overlapped with the L1 region and the 3’-nitro group 
occupied region L2, while the lone pair of electrons of the carbonyl oxygen (O) atom interacted 
with H1 to form a hydrogen bond between the ligand and the receptor.  A second hydrogen 
bond was formed between the oxygen lone pair and H2 of the receptor protein. This alignment 
essentially agrees with what has been discussed in Marder et al. Bioorg. Med. Chem. 9 (2001) 
325-335.   
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Figure 11.  Alignment of 25 within the included volume of the α2β3γ2 subtype. 
 Recently, some flavone-related analogs were prepared (Figure 12)[70] however, these 
flexible ligands with additional lipophilic groups did not bind to any GABAA receptor 
subtype.  It is believed that more planar ligands are required for affinity to these subtypes, as 
the twist chair of the dihydropyran unit may have prevented the fit required for high affinity 
at the Bz BS. Together these data, combined with the work of others, indicate the phenyl ring, 
the carbonyl group and the double bond between C(2) and C(3) of the flavone are the key 
structural features that contribute to the binding affinity of flavonoids to the Bz BS.   
 
O
O
O
O
RR
R = H, Et, COCH3 or acetylene  
Figure 12.  A series of flavone-related analogs that was inactive at the Bz BS. 
 
Analogs of 8-chloropyrazolo[5,1-c][1,2,4]-benzotriazine 5-oxide 
 It has been recognized that small structural modifications in the same chemical family 
could lead to ligands which display different intrinsic activity.  Costanzo et al. reported that 
small structural modifications in analogs of 8-chloropyrazolo[5,1-c][1,2,4]-benzotriazine 5-
oxide produced ligands that displayed different intrinsic activity (Table 3).[71]  When an aryl 
ester function occupied position-3, this class of ligands exhibited high affinity at the Bz BS 
(Table 3, Ki = 11 – 35 nM).  It was proposed the methoxy group of ligand 38, which bound with 
an affinity of 1.0 nM, acted as an electron donor group to enhance the π−π stacking interactions 
between the phenyl ring of this ligand and the receptor protein.  However, it may also be that 
the methoxy group enhanced lipophilic interactions within the L1 region.  Costanzo et al. 
proposed that net inductive and resonance effects as well as the electron donating properties 
(σ = - 0.27) and suitable lipophilic features (- π) of the ligand facilitated this interaction.   
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Table 3.  Affinities of a series of 8-chloropyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide ligands at 
the Bz BS of GABAA receptors.[71] 
N
N
N
N
CO2RCl
O  
Ligand R Ki (nM)
27 Ph 47.5  
28 4-F-Ph 146.0  
29 2-F-Ph 14.0  
30 4-Cl-Ph 49.2  
31 2-Cl-Ph 14.4  
32 4-Me-Ph 51.9  
33     2-Me-Ph 38.3  
34 4-NO2-Ph 41.8  
35 2-NO2-Ph 106.0  
36 4-MeO-Ph 11.6  
37 3-MeO-Ph 41.1  
38 2-MeO-Ph 1.0  
 
Alignment of 38 overlaid with diazepam is shown in Figure 13, wherein the N(1) and 
N(4) functions hydrogen bonded to the H2 and H1 donor receptor sites, respectively.  It was 
felt that the 3-ester function fits into a limited dimension lipophilic pocket in the L1/ L2 region.  
Moreover, the orientation of the lone pair of electrons of the carbonyl oxygen atom of the ester 
function reinforced the receptor binding by means of a 3-centered hydrogen bond (N(4)/ CO/ 
H1).  This hydrogen bond, which is similar to that described for the C(3) ester substituent in β-
carbolines, is also strengthened by the interaction between the 5-oxide group and the nitrogen 
atom with H1. 
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Figure 13.  Alignment of ligand 38 (black) overlayed with diazepam (cyan) within the unified 
pharmacophore/ receptor model and rotated 90 degrees.  
 
Dimer Affinity for the Binding Site 
Some studies which involved monomeric i-BZDs indicated that there might be a limit on the 
size of 3’-imidazo substituents the receptor may accommodate;[47] However, studies that 
involved bivalent ligands suggested otherwise (Table 4).[72, 73]  It is thus possible that the 
spacer for i-BZDs dimers threaded the second portion of the bivalent ligand through and/or 
around the LDi/A2 region that presented steric hindrance for the monomers. 
 
Table 4.  Structures and affinities at the αxβ3γ2 subtype.[47]  NR = not reported; ANT = 
antagonist; IA = inverse agonist; ND = not determined yet. Activity is defined for receptor 
subtype listed in bold. 
                                                                         
               Ro15-1788, 5 (R = Et)                                           β-CCT, 13 (R = H) 
                                                                     WY-S-8, 39 (R = H) 
                                                                                        WY-B-14, 40 (R = TMS) 
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NH
N
t-BuO2C
HN
N
CO2t-Bu
                        
NH
N
t-BuO2C
HN
N
CO2t-Bu
 
                               WY-S-2, 41                                                     WY-S-6, 42 
 
N
N
N
H O
O
O
N
N
N
HO
O
O
MeMe   
N
H
N
H
N
N
 
                             XLi-093, 16                                                           bis(7)-THA, 43                            
N
N
N
H
O
O
N
N
N
H
O
O
O OMeMe  
N
N
N
H
O
O
N
N
N
H
O
O
O
Ph Ph      
                              XLi-210, 44                                                          DMH-III-96, 45                        
                                                                
 
                                           
   Ki (nM)     
Ligand α1 α2 α3 α4 α5 α6 Activity
5, Ro15-1788 0.8 0.9 1.05 NR 0.6 148 ANT 
13, β-CCT 0.72 15 18.9 NR 110.8 5000 IA 
39, WY-S-8 0.97 111 102 NR 208 1980 ND 
40, WY-B-14 6.8 30 36 2000 108 1000 ND 
41, WY-S-2 30 124 100 300 300 4000 ND 
42, WY-S-6 120 1059 3942 NR 5000 5000 ND 
16, XLi-093 1000 1000 858 1550 15 2000 ANT 
43, bis(7)-THA NR NR NR NR NR NR ANT 
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44, XLi-210 231 661 2666 NR 5.4 54.2 ND 
45, DMH-III-96 460 5000 NR NR 5000 5000 ND 
 
Design of the bivalent ligand XLi-093 16 was based on the modeling of the α5−selective 
monomer RY-80 52 in the α5 pharmacophore model. The ability of this ligand to bind (Table 4) 
and fit well within the pharmacophore (Figure 14) requires the 3-carbon linker to be in a linear 
(versus folded) conformation. This linear conformation of XLi-093 has been confirmed both in 
the solid phase and in solution (Figure 14).[74]  The J values calculated from the dihedral 
angles (J = 5.38) were in excellent agreement with those determined from the solution NMR 
spectrum (J = 6.39). Because this bivalent ligand is the most α5-selective ligand reported, the 
enriched selectivity of this dimer and those similar to it, was presumably entropic in nature, as 
the loss of affinity at the other subtypes was profound.[73, 74]   
 
 
Figure 14. Alignments of XLi-093 16 (white) and Ro15-1788 5 (cyan) within the included 
volume of the α5β3γ2 subtype. 
It has been shown via crystallographic and solution NMR studies that modification of 
the aliphatic spacer to a –CH2OCH2– or a -(CH2)2O(CH2)2– group, provided the bivalent ligand 
with a folded conformation (Fig. 15).[74]  Modeling of this type of ligand (e.g. DMH-III-96 45, 
Figure 16) within the α5 pharmacophore model illustrated the inability of bivalent ligands in 
the folded conformation to bind presumably because they are too hindered to access the Bz BS.  
  25
Current data displaying these trends is shown in Table 5, while further studies are underway 
to evaluate the length the lipophilic spacers may contribute toward the selectivity of both the 
benzodiazepine and β-carboline bivalent ligands (e.g. XLi-210 44 and WY-S-6 42).   
 
 
 
 
 
 
Figure 15.  Crystal structures of the linear XLi-093 16 (left) and the folded DMH-III-96 45 
(right).  Figures reprinted with permission.[73, 74]                        
 
 
Table 5.  The molecular composition and stable conformation of various Bz BS bivalent 
ligands.  ND = not determined yet. 
N
N
N
O
O
O
A  
Ligand Monounit 1 Monounit 2 Spacer Conformation 
in solution 
Crystal 
structure 
16, XLi-093 A A (CH2)3 
 
linear      linear 
44, XLi -210 A A (CH2)5 linear ND 
46, XLi -347 A A (CH2)2O(CH2)2 folded ND 
47, XLi-374 A A      CH2OCH2 folded ND 
45, DMH-III-96 - - (CH2)2O(CH2)2 folded      folded 
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Figure 16.  Alignment of a DMH-III-96 45 within the included volume of the α5β3γ2 subtype.  
It is apparent that the folded conformation prevented it from binding to this GABAA subtype.   
Success of XLi-093 and earlier in vitro data on WY-S-8 39 and WY-B-14 40 (Table 4) 
indicated the C(6)-substituent of β-carbolines lies in the LDi region of the pharmacophore 
model or in the extracellular domain of Bz BS.  For this reason, the β-CCT dimer, WY-S-2 41 
was designed and synthesized. Although the α1 subtype selectivity was not amplified with 
this particular β-carboline dimer, the ligand does bind. It was proposed that the two-carbon 
linker was not long enough and that crowding between the second β-CCT unit and the 
receptor protein decreased the binding affinity at α1 subtype, thereby negating potential 
selectivity.[72]  Further evaluation of the β-CCT bivalent ligand with a bis-acetylene linker 
(WY-S-6 42, Figure 17) should shed light on this hypothesis. 
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Figure 17. Alignment of WY-S-2 41 (left) and WY-S-6 42 (right) within the included volume 
of the α1β3γ2 subtype.  
 
Similar to XLi-093, the dimer bis-(7)-THA 43 of Wang et al. was determined to be a 
competitive antagonist at the Bz BS in both electrophysiological experiments and receptor 
binding assays (Table 4).[66]  Although additional experimental data is needed, inspection of 
the alignment of XLi-093 (Figure 14) and our receptor model (see below) indicated the 
aliphatic linker of these bivalent ligands would thread the second half of the dimer through 
the LDi/A2 regions and toward the solvent accessible space outside of the pocket.  
 
Beta-carbolines 
The crystal structures and molecular mechanics simulations of several β-carbolines has 
recently been reported.[75]  In general, substitution at C(3) and C(6) had the greatest effect on 
affinity.  Consistent with the interaction with the H1 descriptor, high affinity ligands were 
always associated with groups able to interact as hydrogen bond acceptors at C(3).  
Furthermore, affinity was much lower for constrained β-carbolines which contained the 
carbonyl group in the anti conformation, in agreement with the proposed 3-centered hydrogen 
bond[36, 44, 46, 54] afforded by many β-carbolines in the stable syn conformation with the H1 
descriptor. 
As previously stated, the C(6)-substituent of β-carbolines lies in the LDi region of the 
unified pharmacophore/ receptor model for inverse agonists and antagonists. However, based 
on the CoMFA studies of Huang et al.,[70] β-carboline agonists have been proposed to take on 
a vertical alignment with respect to the horizontal alignment of inverse agonists and 
antagonists. While only four β-carbolines have been reported to display agonistic activity, each 
of these compounds had a 4-methylmethoxy group that permitted interaction with the H2 
descriptor and partial interaction with the region near the entrance to the L3 pocket (Table 6).  
It was postulated that 6-PBC 12 should display agonistic activity, and indeed, since partial 
occupation of a lipophilic region near the C(6)-substituent is probable (relative to ZK-93423 
11), 6-PBC is a partial agonist.[36, 76]  However, it is likely that the type of activity displayed 
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by 6-PBC may be receptor subtype-dependent, because when evaluated in vivo, it inhibited 
PTZ-induced seizures in a dose-dependent fashion and exhibited anxiolytic activity when 
evaluated in the elevated plus-maze paradigm. Yet, unlike typical 1,4-benzodiazepines, 6-PBC 
12 was devoid of muscle relaxant activity and even antagonized the muscle relaxant/ataxic 
activity of diazepam.[77, 78]  Further studies are needed to fully address this issue.  
 
Table 6.  Structures, affinities at αxβ2γ2 recombinant receptors and modulation by β-
carbolines.  pAg = partial agonist; Ag = agonist. [76] 
N
H
N
R4 R3R6
R5
 
     Ki (nM)       
Ligand R6 R5 R4 R3 α1 α2 α3 α4 α5 α6 Activity
12, 6-PBC On-Pr H MOM CO2Et 0.49 1.21 2.2 NR 2.39 1343 pAg 
11, ZK-93423 OCH2Ph H MOM CO2Et 4.1 4.2 6 NR 4.5 1000 Ag 
48, ZK-91296 H OCH2Ph MOM CO2Et NR NR NR NR NR NR pAg 
49, Abecarnil OCH2Ph H MOM CO2-i-Pr 12.4 15.3 7.5 NR 6 1000 pAg 
 
 
 
Ligands that occupy the L2 region and are selective for α5 containing receptors   
 
RY-24 and related analogs 
 Continued interest in the development of α5 selective ligands goes forward in the CNS 
area for many reasons. One of these involves the localization of these receptors and their 
presumed importance in developmental biology. Over 30 % of GABAA receptors in neonatal 
rat pups are comprised of α5β3γ2 subtypes, whereas they only comprise about 5 % in adult 
  29
rats.[79] In addition, these α5 subtypes are primarily found in the hippocampus,[80] which 
prompted interest in memory and learning.[20]  From the evaluation of Ki values, it was found 
that many 8-substituted i-BZDs, such as RY-24 50 and RY-80 52 and their trimethylsilyl 
precursors 51 and 53 (Table 7), exhibited a significant degree of binding selectivity at the α5 
subtype in vitro.  This observation was in agreement with the previous hypothesis that correct 
occupation of the L2 region can promote α5 selectivity of a ligand.[24, 45]  Therefore, the 
efficacy of the α5-subtype selective ligand RY-24 50 was evaluated in vitro. Recently, it was 
determined that this ligand was a potent inverse agonist at the α5 subtype with a much 
weaker efficacy at the other subtypes (Figure 18). These results confirmed previous binding 
data, which indicated that this ligand was α5-selective due to the lipophilic C(8)-substituent 
which fully occupied the L2 pocket.[23, 24]  The data were also in agreement with previous 
studies in vivo, which indicated that some of these ligands enhanced cognition while other Bz 
BS ligands were not as effective.[20, 81]  Furthermore, ligands devoid of a lipophilic 
substituent at the C(8) position showed no selectivity for the α5 subtype (Table 7).   
 
Table 7.  Structures and affinities of some α5β3γ2-subtype selective ligands. 
              
                                                      56                                     DM-I-81, 55 
Ki (nM)  
Ligand 
 
R8 
 
R3 α1 α2 α3 α5 α6 
50, RY-24    H t-Bu 26.9 26.3 18.7 0.4 5.1 
51, RY-23  TMS t-Bu 197 143 255 2.61 58.6 
52, RY-80    H Et 28.4 21.4 25.8 0.49 28.8 
53, RY-79  TMS Et 121 142 198 5.0 114 
54 H            Et 1.2 2.0 1.1 0.4 > 300 
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55, DM-I-81 Ph NA > 2000 > 2000 > 2000 176 > 2000
56, PWZ-029[82] Cl NA >300 >300 >300 38.8 >300 
 
 Inspection of Table 7 revealed some observations worth noting.  While the lipophilic 
substituent at R8 of RY-24 50 and RY-80 52 decreased the affinity for α1, α2 and α3, it retained 
affinity for α5 and actually increased affinity for the α6 subtype. Furthermore, selective affinity 
of i-BZDs at the α5 subtype was independent of the occupation of the L3 pocket, as illustrated 
by the in vitro data of DM-I-81 55 (Table 7).  This data again supports the importance of the 
occupation of the lipophilic pocket L2 for potent selectivity at α5 subtype.  
 
 
Figure 18.  Subtype efficacy of RY-24 50. Dose response curves for RY-24 in oocytes expressing 
different subunit combinations of GABAA receptors. Subtype combinations are indicated in 
legends. cRNA–injected Xenopus oocytes were held at –60 mV under two-electrode voltage 
clamp. Increasing concentrations of RY-24 were superfused together with a GABA 
concentration eliciting ~ 20% of the maximal current amplitude. RY-24 was pre-applied for 30 
sec before the addition of GABA, which was co-applied with the drugs until a peak response 
was observed. Data were normalized for each curve assuming 100% for the response in the 
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absence of RY-24. RY-24 was made up and diluted as stock solution in DMSO. Final DMSO 
concentrations perfusing the oocyte were 0.1%. Values are presented as mean ± SD of at least 4 
oocytes from at least 2 batches. 
June et al. recently reported the neurobehavioral results of RY-23 and RY-24 in rats.  In 
agreement with previous studies,[23] these α5 selective ligands were highly selective in 
suppressing ethanol-maintained responding (Figure 19).[83] As previously stated, the 
hippocampus contains the greatest concentration of α5-containing receptors in the CNS,[80, 
84] and it is possible that these hippocampal α5 receptors may regulate alcohol-motivated 
responding following systemic administration of an α5-selective agent. Furthermore, RY-24 
also antagonized the motor-impairing and sedative effects of ethanol in Long-Evans rats. 
Combined with additional studies within the ventral pallidum (VP), it has been proposed that 
the GABAergic systems within the VP and hippocampal pathways may represent new 
extensions of the mesolimbic ethanol reward circuitry. Although these data do not strongly 
support a direct role for the modulatory influences of intrinsic efficacy in the behaviors 
examined, the synthesis of α5 subtype selective ligands provides researchers a unique 
opportunity to explore the role of this subtype in the neurobehavioral effects of alcohol.[23, 85] 
In studies involving the α1 subtype, β-CCT 13 and 3-PBC 14 were observed to 
selectively reduce alcohol-motivated behaviors for a variety of experiments.[86, 87]  However, 
unlike the α5 selective inverse agonist RY-23, both the β-carboline antagonists β-CCT and 3-
PBC displayed mixed agonist-antagonist profiles in vivo in alcohol P and HAD rats. Therefore, 
in addition to being able to study the molecular basis of alcohol reinforcement, α1 Bz BS 
ligands which display mixed agonist-antagonist pharmacology in alcohol P and HAD rats may 
be capable of reducing alcohol intake while eliminating or greatly reducing the anxiety 
associated with habitual alcohol, abstinence or detoxification. Thus, these types of ligands may 
be ideal clinical agents for the treatment of alcohol-dependent individuals.[86, 87] 
Additional behavioral studies of RY-24 were performed by Helmstetter et al. and 
provided further support for the role of the hippocampus in anxiety and learning.[20]  
Moreover, the data suggested that Bz BSs within the hippocampus are important for the 
acquisition of fear conditioning.  Although this subtype selective ligand has been shown to be 
an inverse agonist at the α5 subtype,[24, 88] this study suggested that RY-24 may act as an 
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agonist at other alpha subtypes because larger doses of RY-24 were not as anxiogenic as the 
smaller doses and resulted in decreased learning.  Consistent with the studies of Stephens et al. 
using α5 knock-out mice[89] and the efficacy studies of Lüddens, June and Cook et al.,[90] 
these findings support the concept that the pharmacology observed depends upon the dose, 
behavioral paradigm employed and subunit composition activated.  Ligands such as RY-24 
have proven to be valuable in the study of the biochemical and pharmacological properties of 
GABAA receptors and have permitted insight into the role this protein plays in anxiety and 
learning. 
                                           
   
Figure 19.  Suppression of alcohol-motivated responding by RY-24 50 and RY-23 51.[85, 88]  
Left: Dose-response of IP RY-24 (0.0–3.5 mg/ kg) and vehicle on responding maintained by 
ethanol (10 % v/v) (top panel) and water (bottom panel) in male Long-Evans rats.  Right: Dose-
response of unilateral infusions of RY-23 (0.0-40 μg) in the hippocampus on a concurrent fixed-
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ratio (FR4) schedule for ethanol (10 % v/v) (top panel) and saccharin-maintained (0.025 % v/v) 
(bottom panel).  For both studies, *p ≤ 0.05 versus control condition values was determined using 
ANOVA and post hoc Newman-Keuls test.  Each bar represents the mean (± SEM) (n = 15 for 
RY-24 and n = 7 for RY-23).  Figures reprinted with permission of the authors.[85, 88]        
 
QH-ii-066 
Due to the pharmacological profile RY-24 exhibited in vivo, the development of 
additional α5 subtype selective ligands was pursued. Thus, the 7-acetyleno analog of 
diazepam, QH-ii-066 57, was synthesized and was determined to also exhibit a binding and 
functional selectivity at the α5 subtype over the α1 subtype (Table 8).[22]  This was due to the 
full occupation of the L2 pocket, relative to diazepam (Figure 20). To our knowledge, this was 
the first agonist ligand to display some α5 selectivity from the 1,4-benzodiazepine family.  
Importantly, the 7-cyano congener 58 (Table 8) did not potently bind to recombinant receptors 
of the α5 subtype, which is in agreement with earlier work of Haefely and Fryer et al. on the 
SAR of 1,4-benzodiazepines.[91, 92]  This cyano ligand also did not exhibit any subtype 
selectivity, re-emphasizing that occupation of the L2 region with lipophilic groups is important 
for α5 selectivity as well as for high affinity.  The selective efficacy of this QH-ii-066 ligand 
over the α1 subtype was demonstrated by reversing the convulsant actions of RY-24 50, an α5-
selective inverse agonist, in NIH mice.[79]  This ability was not observed at comparable doses 
for the α1-selective agonist zolpidem 7.    
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Figure 20.  Comparison of non-selective diazepam (black) with the α5-selective QH-ii-066 
(cyan) when aligned within the unified pharmacophore/ receptor model.  The acetylene group 
of QH-ii-066 increased the occupation of the L2 region relative to that of diazepam.  
Furthermore, Lelas and Cook et al. have recently determined that although QH-ii-066 
had similar affinity for the DS subtypes in rats, it displayed functional selectivity in vivo, with 
diazepam-like efficacy at the α5 subtype and partial efficacy at the α1 subtype.[22]  The study 
also indicated that this 7-acetyleno substituted diazepam analog exhibited less potency in 
protection against ECS-induced seizures relative to diazepam than against PTZ-induced 
seizures.  Hence, the α1 subtype may play a more prominent role in ECS-induced seizures 
than in PTZ-induced seizures. [22] 
 
Table 8.  Structures and affinities of 1,4-benzodiazepines. 
 
Ki (nM)  
Ligand 
 
R7 α1 α2 α3 α5 α6 
1, diazepam Cl 14 20 15 11 > 3000 
57, QH-ii-066 H 76.3 42.1 47.4 6.8 > 3000 
58 C N 320 310 350 265 > 3000 
 
Comparative Model of the Benzodiazepine Binding Site 
Crystallization of GABAA receptors thus far has not been accomplished, but the 
successful structure determination of the water-soluble acetylcholine binding protein 
(AChBP)[93] has generated much interest in the GABAA receptor community. Although this 
protein shares only ~ 18 % sequence homology with the extracellular domain of the GABAA 
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receptor,[93] the structural resemblance has been estimated to be relatively high (60 – 75 
%).[42] Several comparative modeling studies have used the AChBP structure to derive 
models of the extracellular domain of GABAA receptors[41] [42] (Trudell J. 2002) Following the 
cryo-EM determination of the extracellular and transmembrane domain structure of the nACh 
receptors, these structures also were used as templates for modeling GABAA receptors [94] 
Sequence homology is so low however, that detailed features of the models are highly 
uncertain, and the proposed dockings of Bz BS ligands.[95-97] have a qualitative character and 
do not sufficiently explain the observed differential effects of ligands interacting with different 
receptor subtypes. The experimental structure of the nAChR[98] has provided first data on 
how much the fold can vary between members of a family.[98] From this data the extent to 
which GABAAR subunits differ from each other in structure can be qualitatively extrapolated, 
but not predicted in detail.   
As mentioned before, the majority of GABAA receptors are composed of 1γ, 2α and 2β 
subunits. Each subunit has per convention a “plus” and a “minus” side (Fig. 21). The subunit 
interfaces consequently consist of the plus and minus sides of neighboring subunits. The 
modulatory Bz BS is located at the α+γ− subunit interface and is larger than, but homologous to 
the two agonist (GABA) binding sites, which are located at the β+α− subunit interfaces.[43, 99, 
100] The absolute subunit configuration for the α1β2γ2 GABAA receptor appears to be γβαβα, 
when viewed counter clockwise (from + to - , Figure 21).[42, 101-103] 
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 Figure 21.  Absolute subunit arrangement of the α1β2γ2 GABAA receptor when viewed 
from the synaptic cleft.  The GABA binding sites are located at the β+α− subunit interfaces and 
the modulatory Bz binding site is located at the α+γ− subunit interface. The part of the 
schematically drawn subunits marked by the + indicates loop C of the respective subunits.   
 
 While the γ2 subunit is required for recognition and binding of benzodiazepines as well 
as many other substance classes that act via the Bz BS, [104, 105] it is now clear that sequence 
variations between different α and γ subunits determine subtype selectivity and efficacy of Bz 
BS ligands. (Sieghart, 1995)[104, 105] [106] The Bz BS has been proposed to consist of three 
segments provided by the α+ side, the so‐called “loops A, B and C” and by three segments of 
the γ− , the so‐called “loops D, E and F”. [104, 105] These segments were then confirmed by X-
ray crystallographic and EM-structures of AChBP[93] and the nAChR[98] to form a groove-
like pocket at the interface boundary between subunits that appears to be conserved in the 
entire superfamily.   
 
 
 
Figure 22 Alignment and homology model depiction of the so called “loops A-F” and 
flanking regions of the human sequences of the Bz recognition site in different subunits. The 
homology model is as seen from “outside” of the channel mouth, the membrane would be 
parallel to the lower edge of the image. Key residues are shown in stick representation: Loop A 
His102, loop B Tyr 160 and loop D Phe77.  
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Even later than the nAChR structure, a series of AChBP crystal structures with co-
crystallized ligands appeared [107]. These structures revealed how ligand binding can alter the 
local conformation of the binding site. Particularly loop C has been found to be a highly 
mobile subdomain, additional more subtle changes are seen along the entire subunit 
boundary.[107] These findings are consistent with the hypothesis that many receptor 
conformations exist, that are separated by low energy barriers, and can be stabilized by 
different ligands. Unfortunately it cannot be decided a priori which of the experimental 
structures is the “best” template to model a particular receptor/ligand complex. Depending on 
template and alignment choice, model Bz pockets differ in total volume by as much as 40% 
and can vary by several Angstrom in the distances between key residues in the binding site 
loops.  
Although changes in protein conformation may be minor, it has been demonstrated that 
they can profoundly affect the efficacy of Bz BS ligands. [108] Furthermore, efficacy can vary 
for the same ligand at different GABAA receptor subtypes. [22, 26, 30] As proteins are 
inherently dynamic and able to sample many conformations, and the stabilization of the active 
state relative to the inactive state has been calculated to be less than 1 kcal/mol,[109] it is 
impossible to provide absolute assignments of specific side chains to specific descriptors for 
any particular conformation. This conformational flexibility may imply that residues which 
satisfy certain pharmacophoric descriptors can vary, resulting in a “soft” orientation of the 
pharmacophore in the receptor. Thus, a unified view of a pharmacophore model and a 
homology derived receptor model will assign large areas of lipophilic interaction to specific 
regions in the protein, but allow a flexible assignment of specific interactions such as H-
bridges or pi-pi stacking.  
 
Relative Orientation of the Pharmacophore within the Comparative Model  
Prior to structure determination of the AChBP, we published a review which evaluated 
results of site-directed mutagenesis and provided insights as to where certain side chains in 
the Bz BS might be located relative to the pharmacophoric descriptors.[110]   However, with 
the knowledge gained from recent experimental data and with the aid of our GABAA receptor 
models, built by homology to lymnea AChBP[41], aplysia AChBP and the nAChR[94] an 
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update of the orientation is provided here.  We now propose an orientation which is favored 
by experimental evidence, allows some degree of conformational flexibility which can lead to 
variable assignments for H-bridge interactions, but is based on specific areas of lipophilic 
interactions that are determined by binding site geometry. 
 
Evidence from covalently reactive ligands allows to  position the L2 lipophilic pocket 
Covalent  labeling  studies  contributed  significantly  to  the determination of  residues  that  are 
located within the Bz BS.[111‐113] [96, 114‐116] 
 
Table 9.  Ligands used for affinity labeling studies.[96, 113-116] 
 
Ligand Activity Site of Interaction 
2,  [3H]flunitrazepam Agonist α1H102 
6,  [3H]Ro15-4513 inverse agonist α1Y210 
59  
60  
Agonist 
part. Agonist 
α1H101C (rat) 
α1H101C, α1G157C 
α1V202, α1V211C (rat) 
 
                                        
59         60 
7-isothiocyano-1,4-benzodiazepine       
 
Photoincorporation studies with the agonist [3H]flunitrazepam identified α1H102 of the 
human sequence as the primary site of incorporation.[115] Although it is possible that 
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flunitrazepam is coupling via the nitro group at the 7-position, the coupling group of 
flunitrazepam is currently not known. Studies with the inverse agonist [3H]Ro15-4513  
indicated α1Y210 as the primary site of incorporation [96]. Thus, the azido group at the 7-
position of Ro15-4513 should be in close apposition to α1Y210, assuming no rearrangement of 
the photo-activated intermediate. Further information comes from recent studies reporting the 
covalent coupling of 7-isothiocyano- derivatives of an 1,4-benzodiazepine, (substance 59[114]) 
and of Ro15-1788 (substance 60[116]) to GABAA receptors in which individual amino acid 
residues had been mutated to cysteines. Primary site of reaction of both substances is the rat 
α1H101C mutant that is homologous to α1H102 of the human subunit. Thus, the 7-substituent 
both of 1,4-benzodiazepines and of imidazodiazepines appears to be in apposition to α1H102. 
The imidazobenzodiazepine 60 reacts with additional cysteines in positions corresponding in 
the human sequence to positions α1V203C and α1V212C in the loop C stem, and with α1G158C 
in loop B (see alignment in Fig. 22).  Thus, the 7-substituent of this compound, in agreement 
with the data from photolabeling H102 with flunitrazepam and Y210 with Ro15-4513, is in 
apposition to loop A, the loop C base, and additionally loop B.  
Thus, all the findings from covalently incorporated ligands given above can be 
reconciled by placing the 7-substituent, and thus the L2 descriptor of the unified 
pharmacophore model, between the loop C base near α1V203/α1V212/α1Y210 and loop A 
α1H102. The homology models reveal that this is not only topologically possible, but also 
provides the additional apposition to loop B that is suggested by the reaction of 60 with rat 
α1G157C. Thus, the L2 lipophilic pocket is most likely  formed by the base of loop C, together 
with parts of loop A.   
 
The  A2 descriptor and the LDI region 
Experimental data yields some very convincing evidence for assigning the A2 descriptor and 
the LDI region of lipophilic interaction next to A2 to protein segments close to residues γ2A79 
and γ2T81 at loop D. Certain imidazobenzodiazepines, which occupy the pharmacophore 
volume close to A2 (see Fig. 5), are more sensitive to γ2A79 mutations than classical 
benzodiazepines or benzodiazepines that lack a 3'-imidazo substituent. This was shown in a 
study where mutations of γ2A79 and γ2T81 had little effect on the binding of the agonists 
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diazepam and flunitrazepam, but in a roughly size dependent fashion decreased the affinities 
of antagonist Ro15-1788  and inverse agonists Ro15-4513  [117, 118]. In agreement with other 
studies, midazolam, which lacks a 3’ substituent, behaved more closely to classical 
benzodiazepines than i-BZDs.[38, 117, 119, 120]. This trend is enhanced by rigid and bulky 3'-
imidazo substituents, altogether suggesting that γ2A79 and γ2T81 are located close to the 
region of the Bz BS surrounding the 3' substituent of i-BZDs [117]. The localization of the 3'-
imidazo substituents in the unified pharmacophore model, see Figure 5, thus positions the A2 
and LDI descriptors near residues γ2A79 and γ2T81. Further support for this localization comes 
from the observation that DMCM also looses affinity upon mutagenesis in positions γ2A79 and 
γ2T81 [117, 118], consistent with the alignment of this substance in the pharmacophore. Fig 5 
shows that changes to the protein near the A2 descriptor would in all likelihood not be 
tolerated by DMCM.  
 
Combining homology model and experimental evidence  
If the two assignments discussed above are correct, they should be reflected in results of 
computational ligand docking to homology models of the binding site. Thus, computational 
docking of diazepam and flumazenil was performed in multiple different models based on 
different templates[93, 98, 107] and the best 100 docking poses per model were collected in a 
database. A database query was then formulated to search among the (unrefined) docking 
poses for those with the following properties: The seven membered ring of diazepam or 
flumazenil is in the conformation that is assumed to be the active one[91]; the 7-substituents  
are near residues α1H102/α1V203/ and α1Y210/α1V212 in order to be consistent with the 
covalent labeling data;  the 3’ ester group of flumazenil is near residues γ2A79 and γ2T81. Such 
a query yields docking poses that are consistent with all covalent labeling studies on one hand, 
and with the steric requirements that were found for 3’ substituted 
imidazobenzodiazepines[117] on the other hand. Such poses were indeed present in our 
database, and one representative diazepam pose is shown in Figure 23:  To be consistent with 
the presentation of the pharmacophore and its descriptors so far, the orientation of the 
benzodiazepine binding pocket had to be turned upside down and slightly tilted. 
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Figure 23: The main figure shows a diazepam docking pose in an α1γ2 pocket matching the 
orientation proposed in the text.  Diazepam is rendered space filling, (turquoise: carbon, white: 
hydrogen, green: halogen, red: oxygen, blue: nitrogen),  the protein as ribbon, and key amino 
acids in stick representation. The insert figure shows the empty pocket in the “upright” 
position to facilitate orientation in the main figure, where the model has been turned and tilted 
to bring diazepam approximately into the orientation depicted in the unified pharmacophore 
model, Fig. 3.  In this particular docking pose, His102 and Thr206 could satisfy H2 and H1, 
respectively, and His 102, Val 212 and Tyr 210 would be part of the L2 hydrophobic pocket. 
This positions 7-substituted reactive analogues such as compound 59  into a position where the 
reactive groups find free access to His102,  Tyr 210, Val 212, Val 203. It should be noted that 
due to high uncertainties in model backbone position and side chain rotamers, high accuracy 
docking that correctly reflects all ligand-protein interactions is not feasible, this image is one 
representative of a big cluster of similar docking poses.  
 
This and similar docking poses not only satisfy the two assignments for L2 and A2 that 
are discussed in the sections above, but at the same time position the remaining descriptors as 
follows: H1 can be satisfied by appropriate side chains near the tip of loop C, the LDI region is 
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near the subunit interface, essentially between α1 loop B (Y160) and the γ2  region spanned by 
the interface forming sheet involving M130, T142 and F77; A2 can be satisfied by H-bridge 
accepting sites near α1Y160, γ2A79,  γ2Τ81, γ2M130 and γ2T142. If these proximity relations 
that are found in the docking poses are transferred to the unified pharmacophore model, the 
following picture emerges:  
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Figure 24.  Location of important Bz BS residues relative to the pharmacophoric 
descriptors in two views that correspond to a 90 rotation about L1, with A2 in front, as 
determined by evaluation of experimental data and the comparative model of the α1β2γ2 
GABAA receptor. The ligand shown is diazepam.  Since inverse agonists stabilize protein 
conformations that vary from the conformations preferred by agonists, it seems plausible that 
more than one side chain could satisfy the same descriptor. 
 
Within the different poses that exhibit this orientation, there still is quite some degree of 
variation in structural details. There are several sources for this variability in the 
computationally derived structures: Template and alignment choice, model construction and 
refinement, as well as docking algorithms contribute to the variability of the poses that are 
found.   
This orientation is also strongly supported by the observation that XLi-093, as aligned in 
Fig 14 with the docked diazepam shown above, will be able to thread the portion of the 
molecule not inside the included volume towards the solvent accessible space through the 
subunit boundary.   
Agreement between this orientation of the pharmacophore model inside the structural 
model of the protein with single ligand dockings that have been proposed in the past [95-97] 
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will have to be examined in detail. The overall picture appears to be pointing towards a 
satisfactory orientation of the pharmacophore model in the pocket, and for those instances 
where there could be a discrepancy, further experiments will clarify.  
Refinement of the predicted protein-ligand complexes with the aid of the unified 
pharmacophore model appears to be a very promising approach to arrive at 3D structures that 
are of sufficient accuracy to be used for structure guided drug design. Studies that combine 
advanced protein modeling techniques with the classical pharmacophore approach are 
currently underway.  
 
Conclusion 
A unified pharmacophore model incorporating many substance classes that act at the DS and 
DI benzodiazepine binding sites of GABAA receptors has been updated to include new 
substance classes. Compound development guided by this pharmacophore model has led to 
new agents with interesting pharmacological profiles, particularly enhanced preference for α2 
or α5 containing GABAA receptor subtype. Based on the evaluation of experimental data and  
comparative models of the α1β2γ2 GABAA receptor, the location of several residues relative to 
the descriptors of the pharmacophore/receptor model has been proposed. Although no 
absolute assignments were made regarding which amino acids satisfy the pharmacophoric 
descriptors, experimental data strongly indicated definite trends with regard to how ligands of 
varying pharmacological activity are oriented within the receptor. Because the unified 
pharmacophore/receptor model accounts for the binding and activity profiles at the six 
GABAA receptor subtypes containing any one of the different alpha subunits, the proposed 
orientation should also be similar within the different models[102] of the various receptor 
subtypes.  Information to be immediately gained from this proposed orientation can have far 
reaching benefits, not only for the rational design of selective ligands and the interpretation of 
ligand docking results, but also for the identification and evaluation of possible roles certain 
residues may have within the pocket. As structure determination of the GABAA receptor is 
eagerly awaited, it is hoped that this proposed orientation may be used by others to gain 
additional insight into the potential mechanisms underlying binding and modulation at the Bz 
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site, all of which will lead to a better understanding of the structure and function of GABAA 
receptors.     
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